256
Participants
Start Date
May 25, 2016
Primary Completion Date
June 28, 2019
Study Completion Date
June 28, 2019
ABP 798
ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
Rituximab
Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
Research Site, Gosford
Research Site, Frankston
Research Site, Plovdiv
Research Site, Perth
Research Site, Stara Zagora
Research Site, Batumi
Research Site, Cáceres
Research Site, Candiolo
Research Site, Cadiz
Research Site, Athens
Research Site, Athens
Research Site, Córdoba
Research Site, La Rochelle
Research Site, Milan
Research Site, Milan
Research Site, Roanoke
Research Site, Bergamo
Research Site, Flensburg
Research Site, Brescia
Research Site, Patra
Research Site, Madrid
Research Site, Majadahonda
Research Site, Chihuahua City
Research Site, Bordeaux
Research Site, Aviano
Research Site, Kassel
Research Site, Padua
Research Site, Cesson-Sévigné
Research Site, Salamanca
Research Site, La Laguna Tenerife
Research Site, Mount Sterling
Research Site, Daegu
Research Site, Daegu
Research Site, Parma
Research Site, Zanesville
Research Site, Ulsan
Research Site, Rimini
Research Site, Ravenna
Research Site, Pusan
Research Site, Münster
Research Site, Dnipropetrovsk
Research Site, Jinju
Research Site, Chernivtsi
Research Site, Billings
Research Site, Pesaro
Research Site, Boulogne-sur-Mer
Research Site, Clermont-Ferrand
Research Site, San Giovanni Rotondo
Research Site, Freiburg im Breisgau
Research Site, Poitiers
Research Site, Augsburg
Research Site, Uzhhorod
Research Site, Würzburg
Research Site, Bogota
Research Site, Timișoara
Research Site, Vadodara
Research Site, Surat
Research Site, Nashik
Research Site, Târgu Mureş
Research Site, Târgu Mureş
Research Site, Bangalore
Research Site, Mangalore
Research Site, Be’er Ya‘aqov
Research Site, Encinitas
Research Site, Windsor
Research Site, Medellín
Research Site, Prague
Research Site, Ostrava - Poruba
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Leipzig
Research Site, Pune
Research Site, Bikaner
Research Site, Terni
Research Site, Chiba
Research Site, Fukuoka
Research Site, Maebashi
Research Site, Kobe
Research Site, Tsu
Research Site, Utsunomiya
Research Site, Tachikawa
Research Site, Tokyo
Research Site, Mexico City
Research Site, Torun
Research Site, Krakow
Research Site, Legnica
Research Site, Gdansk
Research Site, Bucharest
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Sabadell
Research Site, Barcelona
Research Site, Kyiv
Research Site, Kyiv
Lead Sponsor
Amgen
INDUSTRY